Key Features and Benefits
- Accurate: Detects 98 targets on SARS-CoV-2 RNA for highly accurate detection of mutations
- Comprehensive: Reports consensus sequence when +90 amplicons are detected
- Quality Controlled: Built-in quality control in every reaction
- Flexible: Seamless end-to-end workflow; temperature specification allows use of different thermocyclers
This amplicon-based next-generation sequencing (NGS) assay is designed to help clinical research labs identify novel strains of SARS-CoV-2. It includes 2019-nCoV primers to detect mutations and characterize RNA from the SARS-CoV-2 virus.
Rapid, Low-Throughput SARS-CoV-2 Detection
The Illumina COVIDSeq Assay accommodates a low number of samples. The workflow includes steps for viral RNA extraction, RNA-to-cDNA conversion, PCR, library preparation, sequencing, analysis, and report generation.
Design and Quality Control
The assay leverages a modified version of the publicly available ARTIC multiplex PCR protocol, with 98 amplicons designed to amplify SARS-CoV-2 virus-specific sequences, combined with proven Illumina sequencing technology. A 63°C annealing temperature at the PCR step improves variant analysis—providing important insight into the SARS-CoV-2 strain present in the sample.
An optional primer pool is also available. It is based on ARTIC community v4 design and includes 99 amplicons and no human controls. The kit volume is sufficient for 384 samples.
Upload consensus sequence information (FASTA file) into open software tools to assign lineage and annotate mutations. For added convenience, upload files to the NCBI and/or GISAID App directly through BaseSpace Sequencing Hub.
Questions about whether this assay is a good fit for your needs? Contact Us today.